{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:02:07Z","timestamp":1793520127706,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,6]]},"DOI":"10.7759\/cureus.85457","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T10:53:34Z","timestamp":1749207214000},"source":"Crossref","is-referenced-by-count":2,"title":["Comparative Efficacy and Safety of Daily Versus Alternate-Day Dosing of Rosuvastatin in Diabetic Dyslipidemia: An Open-Label Clinical Trial"],"prefix":"10.7759","author":[{"given":"Nalini","family":"Kumari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetna A","family":"Shamkuwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay M","family":"Motghare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh N","family":"Dakhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Global Burden of Disease 2021: Findings From the GBD 2021 Study","author":"Global Burden of Disease Collaborative Network","year":"2024","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease 2021: Findings From the GBD 2021 Study. Institute for Health Metrics and Evaluation (IHME), Seattle (WA); 2024."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110945","article-title":"Erratum to \"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045\" [Diabetes Res. Clin. Pract. 183 (2022) 109119]","volume":"204","author":"Sun H","year":"2023","unstructured":"Sun H, Saeedi P, Karuranga S, et al.. Erratum to \"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045\" [Diabetes Res. Clin. Pract. 183 (2022) 109119]. Diabetes Res Clin Pract. 2023, 204:110945. 10.1016\/j.diabres.2023.110945","journal-title":"Diabetes Res Clin Pract"},{"key":"ref3","article-title":"IDF Diabetes Atlas, 10th Edition","author":"Magliano DJ","year":"2021","unstructured":"Magliano DJ, Boyko EJ. IDF Diabetes Atlas, 10th Edition. International Diabetes Federation, Brussels; 2021."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.25259\/NMJI_655_23","article-title":"Lessons learnt from the ICMR-INDIAB study","volume":"36","author":"Mohan V","year":"2023","unstructured":"Mohan V, Anjana RM, Tandon N. Lessons learnt from the ICMR-INDIAB study. Natl Med J India. 2023, 36:137-9. 10.25259\/NMJI_655_23","journal-title":"Natl Med J India"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30199-7","article-title":"Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study (Erratum in: Lancet Diabetes Endocrinol. 2017 Aug;5(8):e5)","volume":"5(8)","author":"Anjana RM","year":"2017","unstructured":"Anjana RM, Deepa M, Pradeepa R, et al.. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study (Erratum in: Lancet Diabetes Endocrinol. 2017 Aug;5(8):e5) . Lancet Diabetes Endocrinol. 2017, 5(8):585-96. 10.1016\/S2213-8587(17)30199-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.10.010","article-title":"Prevalence of macro- and microvascular complications among patients with type 2 diabetes in Iran: a systematic review","volume":"83","author":"Amini M","year":"2009","unstructured":"Amini M, Parvaresh E. Prevalence of macro- and microvascular complications among patients with type 2 diabetes in Iran: a systematic review. Diabetes Res Clin Pract. 2009, 83:18-25. 10.1016\/j.diabres.2008.10.010","journal-title":"Diabetes Res Clin Pract"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet1066","article-title":"Dyslipidemia in type 2 diabetes mellitus","volume":"5","author":"Mooradian AD","year":"2009","unstructured":"Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009, 5:150-9. 10.1038\/ncpendmet1066","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"ref8","article-title":"Role of HDL in those with diabetes","volume":"16","author":"Santos-Gallego CG","year":"2014","unstructured":"Santos-Gallego CG, Rosenson RS. Role of HDL in those with diabetes. Curr Cardiol Rep. 2014, 16:512.","journal-title":"Curr Cardiol Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.008720","article-title":"Global and regional patterns in cardiovascular mortality from 1990 to 2013","volume":"132","author":"Roth GA","year":"2015","unstructured":"Roth GA, Huffman MD, Moran AE, Feigin V, Mensah GA, Naghavi M, Murray CJ. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation. 2015, 132:1667-78. 10.1161\/CIRCULATIONAHA.114.008720","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.008729","article-title":"Cardiovascular diseases in India: current epidemiology and future directions","volume":"133","author":"Prabhakaran D","year":"2016","unstructured":"Prabhakaran D, Jeemon P, Roy A. Cardiovascular diseases in India: current epidemiology and future directions. Circulation. 2016, 133:1605-20. 10.1161\/CIRCULATIONAHA.114.008729","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwae025","article-title":"Obesity and cardiovascular health","volume":"31","author":"Welsh A","year":"2024","unstructured":"Welsh A, Hammad M, Pi\u00f1a IL, Kulinski J. Obesity and cardiovascular health. Eur J Prev Cardiol. 2024, 31:1026-35. 10.1093\/eurjpc\/zwae025","journal-title":"Eur J Prev Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner Z","year":"2011","unstructured":"Reiner Z, Catapano AL, De Backer G, et al.. ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011, 32:1769-818. 10.1093\/eurheartj\/ehr158","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.35366\/100791","article-title":"Diabetic dyslipidemia","volume":"32(s3)","author":"Parcero-Vald\u00e9s JJ","year":"2021","unstructured":"Parcero-Vald\u00e9s JJ . Diabetic dyslipidemia.  Cardiovasc Metab Sci\t. 2021, 32(s3):s168-72. 10.35366\/100791","journal-title":"Cardiovasc Metab Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2005.12.026","article-title":"Lipid and lipoprotein dysregulation in insulin resistant states","volume":"368","author":"Avramoglu RK","year":"2006","unstructured":"Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta. 2006, 368:1-19. 10.1016\/j.cca.2005.12.026","journal-title":"Clin Chim Acta"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001167","article-title":"Correction to: Heart disease and stroke statistics-2023 update: a report from the American Heart Association","volume":"148","year":"2023","unstructured":"Correction to. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023, 148:e4. 10.1161\/CIR.0000000000001167","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2174\/157016112803520864","article-title":"Mechanisms of diabetic dyslipidemia: relevance for atherogenesis","volume":"10","author":"Arca M","year":"2012","unstructured":"Arca M, Pigna G, Favoccia C. Mechanisms of diabetic dyslipidemia: relevance for atherogenesis. Curr Vasc Pharmacol. 2012, 10:684-6. 10.2174\/157016112803520864","journal-title":"Curr Vasc Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3185","article-title":"Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study","volume":"98","author":"Lorenzo C","year":"2013","unstructured":"Lorenzo C, Hartnett S, Hanley AJ, Rewers MJ, Wagenknecht LE, Karter AJ, Haffner SM. Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study. J Clin Endocrinol Metab. 2013, 98:1622-30. 10.1210\/jc.2012-3185","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do R","year":"2013","unstructured":"Do R, Willer CJ, Schmidt EM, et al.. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013, 45:1345-52. 10.1038\/ng.2795","journal-title":"Nat Genet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference BA","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al.. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017, 38:2459-72. 10.1093\/eurheartj\/ehx144","journal-title":"Eur Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein JL","year":"2015","unstructured":"Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015, 161:161-72. 10.1016\/j.cell.2015.01.036","journal-title":"Cell"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n J","year":"2020","unstructured":"Bor\u00e9n J, Chapman MJ, Krauss RM, et al.. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020, 41:2313-30. 10.1093\/eurheartj\/ehz962","journal-title":"Eur Heart J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.20.3.830","article-title":"LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: the Strong Heart Study","volume":"20","author":"Howard BV","year":"2000","unstructured":"Howard BV, Robbins DC, Sievers ML, et al.. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: the Strong Heart Study. Arterioscler Thromb Vasc Biol. 2000, 20:830-5. 10.1161\/01.atv.20.3.830","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.03.072","article-title":"Small dense low-density lipoprotein cholesterol predicts atherosclerotic cardiovascular disease in the Copenhagen general population study","volume":"75","author":"Balling M","year":"2020","unstructured":"Balling M, Nordestgaard BG, Langsted A, Varbo A, Kamstrup PR, Afzal S. Small dense low-density lipoprotein cholesterol predicts atherosclerotic cardiovascular disease in the Copenhagen general population study. J Am Coll Cardiol. 2020, 75:2873-5. 10.1016\/j.jacc.2020.03.072","journal-title":"J Am Coll Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010363","article-title":"Dyslipidemia and cardiovascular disease: current knowledge, existing challenges, and new opportunities for management strategies","volume":"12","author":"Du Z","year":"2023","unstructured":"Du Z, Qin Y. Dyslipidemia and cardiovascular disease: current knowledge, existing challenges, and new opportunities for management strategies. J Clin Med. 2023, 12:10.3390\/jcm12010363","journal-title":"J Clin Med"},{"key":"ref25","article-title":"Statin medications","author":"Sizar O","year":"2025","unstructured":"Sizar O, Khare S, Patel P, et al.. Statin medications. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92(2)","author":"Jones P","year":"2003","unstructured":"Jones P, Davidson M, Stein E, Bays H, et al.. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003, 92(2):152-60. 10.1016\/s0002-9149(03)00530-7","journal-title":"Am J Cardiol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(03)00004-3","article-title":"Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals","volume":"91(5A)","author":"Shepherd J","year":"2003","unstructured":"Shepherd J, Hunninghake D, Barter P, McKenney J, Hutchinson H. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.  Am J Cardiol. 2003, 91(5A):11C-17C. 10.1016\/s0002-9149(03)00004-3","journal-title":"Am J Cardiol"},{"key":"ref28","article-title":"HMG-CoA reductase inhibitors [updated 2023 Jul 3]","author":"Bansal AB","year":"2025","unstructured":"Bansal AB, Cassagnol M. HMG-CoA reductase inhibitors [updated 2023 Jul 3]. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.05.012","article-title":"Correction to: 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","year":"2019","unstructured":"Correction to. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019, 73:3234-7. 10.1016\/j.jacc.2019.05.012","journal-title":"J Am Coll Cardiol"},{"key":"ref30","unstructured":"CRESTOR trial. (2015). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021366s031lbl.pdf."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/s0828-282x(09)70480-5","article-title":"Efficacy of alternate day versus daily dosing of rosuvastatin","volume":"25","author":"Dulay D","year":"2009","unstructured":"Dulay D, LaHaye SA, Lahey KA, Day AG. Efficacy of alternate day versus daily dosing of rosuvastatin. Can J Cardiol. 2009, 25:e28-31. 10.1016\/s0828-282x(09)70480-5","journal-title":"Can J Cardiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111687","article-title":"Statin-associated myopathy: emphasis on mechanisms and targeted therapy","volume":"22","author":"Vinci P","year":"2021","unstructured":"Vinci P, Panizon E, Tosoni LM, et al.. Statin-associated myopathy: emphasis on mechanisms and targeted therapy. Int J Mol Sci. 2021, 22:11687. 10.3390\/ijms222111687","journal-title":"Int J Mol Sci"},{"key":"ref33","unstructured":"CRESTOR trial. (2024). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/021366s046lbl.pdf."},{"key":"ref34","unstructured":"CRESTOR\u00ae (rosuvastatin calcium) PRODUCT MONOGRAPH. ( 2024). https.\/\/www.astrazeneca.ca\/content\/dam\/az-ca\/downloads\/productinformation\/crestor-product-monograph-en.pdf."},{"key":"ref35","article-title":"Dyslipidemia in patients with diabetes","author":"Feingold KR","year":"2000","unstructured":"Feingold KR, Ahmed SF, Anawalt B, et al.. Dyslipidemia in patients with diabetes. Endotext [Internet]. MDText.com, Inc., South Dartmouth (MA); 2000."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.13044","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement","volume":"328","author":"Mangione CM","year":"2022","unstructured":"Mangione CM, Barry MJ, Nicholson WK, et al.. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022, 328:746-53. 10.1001\/jama.2022.13044","journal-title":"JAMA"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.5551\/jat.RV17023","article-title":"Pathophysiology of diabetic dyslipidemia","volume":"25","author":"Hirano T","year":"2018","unstructured":"Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb. 2018, 25:771-82. 10.5551\/jat.RV17023","journal-title":"J Atheroscler Thromb"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13040943","article-title":"Low-density lipoprotein cholesterol-lowering drugs: a narrative review","volume":"13","author":"Ferri N","year":"2024","unstructured":"Ferri N, Ruscica M, Fazio S, Corsini A. Low-density lipoprotein cholesterol-lowering drugs: a narrative review. J Clin Med. 2024, 13:943. 10.3390\/jcm13040943","journal-title":"J Clin Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias","volume":"37","author":"Catapano AL","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, et al.. 2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016, 37:2999-3058. 10.1093\/eurheartj\/ehw272","journal-title":"Eur Heart J"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13071894","article-title":"Rosuvastatin-based lipid-lowering therapy for the control of LDL cholesterol in patients at high vascular risk","volume":"13","author":"Mostaza JM","year":"2024","unstructured":"Mostaza JM, Escobar C. Rosuvastatin-based lipid-lowering therapy for the control of LDL cholesterol in patients at high vascular risk. J Clin Med. 2024, 13:1894. 10.3390\/jcm13071894","journal-title":"J Clin Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2011.09.006","article-title":"Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers","volume":"413","author":"Li JJ","year":"2012","unstructured":"Li JJ, Yang P, Liu J, et al.. Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers. Clin Chim Acta. 2012, 413:139-42. 10.1016\/j.cca.2011.09.006","journal-title":"Clin Chim Acta"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.18203\/2319-2003.ijbcp20243835","article-title":"Effectiveness and safety of daily versus alternate-day rosuvastatin dose in dyslipidemic patients: a prospective, randomized and open-label study","volume":"14","author":"Dafda A","year":"2025","unstructured":"Dafda A, Singh NR, Chhabra A. Effectiveness and safety of daily versus alternate-day rosuvastatin dose in dyslipidemic patients: a prospective, randomized and open-label study. Int J Basic Clin Pharmacol. 2025, 14:50-4. 10.18203\/2319-2003.ijbcp20243835","journal-title":"Int J Basic Clin Pharmacol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.5455\/njppp.2023.13.03115202218052022","article-title":"Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients","volume":"13","author":"Vasa M","year":"2023","unstructured":"Vasa M, Polasani MR, Mala RD, Yadav A, Venkatrao PB. Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients. Natl J Physiol Pharm Pharmacol. 2023, 13:21-6. 10.5455\/njppp.2023.13.03115202218052022","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"ref44","article-title":"Lipidology update: targets and timing of well-established therapies","author":"Luigina G","year":"2024","unstructured":"Luigina G, Alessandro L. Lipidology update: targets and timing of well-established therapies. Eur Soc Cardiol. 2024,","journal-title":"Eur Soc Cardiol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02022.x","article-title":"Lipid-altering efficacy of ezetimibe\/simvastatin 10\/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - the IN-CROSS study","volume":"63","author":"Farnier M","year":"2009","unstructured":"Farnier M, Averna M, Missault L, et al.. Lipid-altering efficacy of ezetimibe\/simvastatin 10\/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - the IN-CROSS study. Int J Clin Pract. 2009, 63:547-59. 10.1111\/j.1742-1241.2009.02022.x","journal-title":"Int J Clin Pract"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.33393\/dti.2008.1333","article-title":"Therapies to Increase ApoA-I and HDL-cholesterol levels","volume":"3(1)","author":"Brown WM","year":"2008","unstructured":"Brown WM, Chiacchia FS. Therapies to Increase ApoA-I and HDL-cholesterol levels. Drug Target Insights. 2008, 3(1):10.33393\/dti.2008.1333","journal-title":"Drug Target Insights"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.18203\/2319-2003.ijbcp20163234","article-title":"Efficacy of alternate day versus everyday dosing of rosuvastatin in hyperlipidemia","volume":"5","author":"Panchavarthi C","year":"2016","unstructured":"Panchavarthi C, Shankara UT, Pakanati V, et al.. Efficacy of alternate day versus everyday dosing of rosuvastatin in hyperlipidemia. Int JBasic Clin Pharmacol \r\n. 2016, 5:2045-50. 10.18203\/2319-2003.ijbcp20163234","journal-title":"Int JBasic Clin Pharmacol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/j.0197-3118.2005.04404.x","article-title":"Decreasing LDL cholesterol and medication cost with every-other-day statin therapy","volume":"8","author":"Juszczyk MA","year":"2005","unstructured":"Juszczyk MA, Seip RL, Thompson PD. Decreasing LDL cholesterol and medication cost with every-other-day statin therapy. Prev Cardiol. 2005, 8:197-9. 10.1111\/j.0197-3118.2005.04404.x","journal-title":"Prev Cardiol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.18203\/2319-2003.ijbcp20174769","article-title":"A comparative study of atorvastatin and rosuvastatin in dyslipidemia","volume":"6(11)","author":"Thapa R","year":"2003","unstructured":"Thapa R, Rai P, Mahara, et al.. A comparative study of atorvastatin and rosuvastatin in dyslipidemia. Int J Basic Clin Pharmacol. 2003, 6(11):2551-5. 10.18203\/2319-2003.ijbcp20174769","journal-title":"Int J Basic Clin Pharmacol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson RS","year":"2014","unstructured":"Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014, 8:S58-71. 10.1016\/j.jacl.2014.03.004","journal-title":"J Clin Lipidol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin toxicity","volume":"124","author":"Ward NC","year":"2019","unstructured":"Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res. 2019, 124:328-50. 10.1161\/CIRCRESAHA.118.312782","journal-title":"Circ Res"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-017-6743-0","article-title":"Efficacy and safety of alternate-day versus daily dosing of statins: a systematic review and meta-analysis","volume":"31","author":"Awad K","year":"2017","unstructured":"Awad K, Mikhailidis DP, Toth PP, et al.. Efficacy and safety of alternate-day versus daily dosing of statins: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2017, 31:419-31. 10.1007\/s10557-017-6743-0","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/362732-comparative-efficacy-and-safety-of-daily-versus-alternate-day-dosing-of-rosuvastatin-in-diabetic-dyslipidemia-an-open-label-clinical-trial","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T10:53:36Z","timestamp":1749207216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/362732-comparative-efficacy-and-safety-of-daily-versus-alternate-day-dosing-of-rosuvastatin-in-diabetic-dyslipidemia-an-open-label-clinical-trial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":52,"URL":"https:\/\/doi.org\/10.7759\/cureus.85457","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,6]]}}}